Company News: Forest, Pri-Med Institute and pmiCME

Share this article:
Forest reported fiscal third-quarter 2010 adjusted diluted earnings per share of $0.97, beating analyst consensus by $0.11. Higher-than-expected sales drove the earnings and reflect Forest's success with its new product launches Savella (for fibromyalgia, launched in April 2009), which recorded sales of $15.4 million in the fiscal third quarter, and Bystolic (for hypertension, launched in Jan. 2008), which posted sales of $47.5 million vs. $21.0 million in last year's fiscal third quarter. Overall sales surged 8.4% to $997.0 million, from $920.0 million in the year-ago period. Anxiety drug Lexapro sales dipped 0.5% from the year-ago period to $582.6 million, while Alzheimer's drug Namenda rose 17.3% to $282.5 million during the quarter.

CME firm Pri-Med Institute has changed its name to pmiCME, a name which more clearly distinguishes it as an accredited provider, the company said last week. The change became effective Jan. 1. “This step is being taken to ensure clarity, transparency and disclosure as the use of the Pri-Med name is being increasingly applied to platforms and activities that are not certified CME,” read a statement. pmiCME provides accreditation and education in partnership with other education providers, as well as for Pri-Med, the brand that is owned and operated by M|C Communications. “The evolution to our new name—pmiCME—ties us more closely to what we do—CME and continuing education for other health care professionals as the independent division of M|C Holding Corp.,” said Marissa Seligman, PharmD, chief clinical & regulatory affairs and compliance officer, M|C Holding Corp., and SVP, pmiCME.
Share this article:

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.